Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hib-MenAC conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- Royal (Wuxi) Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Hib-MenAC conjugate vaccine is a trivalent polysaccharide-protein conjugate vaccine developed by Royal (Wuxi) Biological Co., Ltd. to protect infants and children against invasive diseases caused by *Haemophilus influenzae* type b (Hib) and *Neisseria meningitidis* serogroups A and C. The vaccine is composed of the capsular polysaccharides of these three pathogens, each individually conjugated to a tetanus toxoid (TT) carrier protein. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, thereby enhancing immunogenicity and inducing immunological memory, particularly in infants under two years of age. Designed as a combination product, it aims to simplify pediatric immunization schedules in China by replacing separately administered MenAC and Hib vaccines with a single intramuscular injection. The vaccine has undergone Phase III clinical evaluation to assess its safety and immunogenicity in infants (6-23 months) and children (2-5 years).
- Brand names
- HIBACON
- Other names
- A+C+hib Conjugate VaccineHib-MenAC-TT vaccineCombined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus toxoid conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)
Beyond the preview
Go deeper on Hib-MenAC conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hib-MenAC conjugate vaccine.